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Diabetic retinopathy is one of the most common causes of blindness in North America. Several signaling mechanisms are
activated secondary to hyperglycemia in diabetes, leading to activation of vasoactive factors. We investigated a novel pathway,
namely extracellular signal regulated kinase 5 (ERK5) mediated signaling, in modulating glucose-induced vascular endothelial
growth factor (VEGF) expression. Human microvascular endothelial cells (HMVEC) were exposed to glucose. In parallel, retinal
tissues from streptozotocin-induced diabetic rats were examined after 4 months of follow-up. In HMVECs, glucose caused initial
activation followed by deactivation of ERK5 and its downstream mediators myocyte enhancing factor 2C (MEF2C) and Kruppel-
likefactor2(KLF2)mRNAexpression.ERK5inactivationfurtherledtoaugmentedVEGFmRNAexpression.Furthermore,siRNA
mediated ERK5 gene knockdown suppressed MEF2C and KLF2 expression and increased VEGF expression and angiogenesis.
On the other hand, constitutively active MEK5, an activator of ERK5, increased ERK5 activation and ERK5 and KLF2 mRNA
expression and attenuated basal- and glucose-induced VEGF mRNA expression. In the retina of diabetic rats, depletion of ERK5,
KLF2 and upregulation of VEGF mRNA were demonstrated. These results indicated that ERK5 depletion contributes to glucose
induced increased VEGF production and angiogenesis. Hence, ERK5 may be a putative therapeutic target to modulate VEGF
expression in diabetic retinopathy.
1.Introduction
Diabetic retinopathy (DR) is a devastating complication of
diabetes, manifesting primarily as vascular structural and
functional changes in the retina, eventually leading to vision
loss. DR is the most common cause of blindness in North
America in the 25–74-years age group [1]. Glucose-induced
increased production of vasoactive factors are characteristics
of all chronic diabetic complications including DR. Vascular
endothelial growth factor (VEGF) is a key vasoactive factor,
which is upregulated in the retina in DR. VEGF is an
important mediator of increased vascular permeability in
early DR and a major contributor of retinal neovascular-
ization in proliferative DR [1–4]. In human, VEGF mRNA
expression is increased in the neovascular membranes from
diabetic patients obtained by vitrectomy compared to those
removed from the nondiabetic individuals [4]. Augmented
VEGF protein production was further observed in human
retina in diabetes using immunohistochemistry [2, 3]. We
and others have demonstrated increased VEGF expression
in the retina of streptozotocin-induced diabetic rat model
causing increased microvascular permeability [5, 6]. In a
murine model of ischemic retinopathy, inhibition of VEGF
has also been shown to suppress retinal neovascularization
[7]. Furthermore exposure of endothelial cells (ECs) to high
glucose causes increased VEGF expression [8, 9]. VEGF
mRNA and protein expression are stimulated by long-
term high glucose treatment in bovine microvascular retinal
ECs [10]. Previous studies in our lab have demonstrated
that VEGF interacts with other vasoactive factors such as
endothelin-1 (ET-1) in mediating glucose-induced increased
permeability in the ECs [5, 8]. These data indicate that
VEGF plays an important role in causing increased vascular
permeability and angiogenesis in DR [2, 3]. Several glucose
induced signaling mechanisms such as protein kinase C
(PKC) activation, nonenzymatic glycation and mitogen-
activated protein kinase (MAPK) activation are instrumental
in causing glucose induced alteration of vasoactive factors in
diabetes [11].
ERK5,alsoknownasbigMAPK1(BMK1),wasidentiﬁed
as a member of the MAPK family in 1995 [12, 13]. ERK5
is a protein of 816 amino acid residues with a large COOH2 Journal of Ophthalmology
terminal. BMK1 is diﬀerent from other MAPK as it has
a transcriptional activation domain. MAPK/ERK kinase 5
(MEK5) is the speciﬁc MAPK kinase for ERK5. ERK5
is highly expressed in the ECs [14]. Studies on ERK5
knockout mice have shown that the ERK5 pathway is
critical for endothelial function and for maintaining blood
vessel integrity [15]. In addition, ERK5 signaling mediates
stress response in the ECs [14, 16]. More recently, studies
have shown that ERK5 signaling controls migration and
morphology of the ECs [17].
It has been demonstrated that in the nondiabetic condi-
tions, ERK5 have a regulatory role on VEGF expression [18–
20]. In mouse, mutant ERK5 gene (homozygous knockout)
increases expression of VEGF mRNA and protein [19, 20].
Moreover, ERK5 represses VEGF expression in bovine lung
microvascular ECS [18]. Investigations have shown that
overexpression of Krupple-like factor 2 (KLF2), a target
gene of ERK5, inhibited VEGF receptor promoter activation
[21]. KLF2 overexpression also counteracts VEGF-mediated
inﬂammatory responses in the ECs [22]. In addition,
microarray studies have revealed that KLF2 overexpression
decreases mRNA expression of human VEGF receptor 2
[23, 24]. Hence it is potentially possible that ERK5 through
KLF2 may also have a regulatory role on the production
of VEGF in DR. However such possibilities have not been
investigated. Here, we examined the mechanisms of glucose-
induced ERK5-mediated regulation of VEGF in the ECs
and in the retina of diabetic rats. We further explored the
signiﬁcance of such changes in DR.
2.MaterialsandMethods
2.1. Cell Culture. A dermal-derived human microvascular
endothelial cell (HMVEC) was obtained from Lonza, Inc.
(Walkersville, MD). HMVECs were grown in endothelial
cell basal medium 2 (EBM-2, Lonza, Walkersville, MD)
containing human epidermal growth factor (hEGF), 1‰;
Hydrocortisone, 0.4‰; gentamycin, 1‰; fetal bovine serum
(FBS), 10‰; vascular endothelial growth factor (VEGF),
1‰; human ﬁbroblast growth factor-basic (hFGF-B), 4‰;
long R3 insulin-like growth factor (R3-IGF-1), 1‰; Ascor-
bic Acid, 1‰. In EBM2, the glucose concentration was
5mmol/l. Cells were grown in 25cm2 tissue culture ﬂasks
and maintained in a humidiﬁed atmosphere containing 5%
CO2 at 37
◦C. Cells at 80% conﬂuence were growth arrested
by incubation in serum-free medium overnight prior to
incubation with high glucose (25mmol/l D-glucose) or
osmotic control (L-glucose) of the same concentration.
2.2. Gain and Loss of Function Studies. For gain of func-
tion study, constitutively active human recombinant MEK5
(CAMEK5, 20MOI) adenovirus (Cell Biolabs, San Diego,
CA) was used to activate ERK5. Cells were seeded in 6-
well plate, cultured overnight and infected with adenovirus
for 48hrs. A nonspeciﬁc GFP adenovirus with the same
multiplicity of infection (20MOI) was used as a negative
control. For loss of function study, ERK5 siRNA (siERK5)
Table 1: Oligonucleotide sequences for real-time PCR.
Gene Sequence 5  → 3 
ERK5 (human)
CTGGCTGTCCAGATGTGAA
ATGGCACCATCTTTCTTTGG
MEF2C
(human)
TACAACGAGCCGCATGAGAG
CCTGTGTTACCTGCACTTGG
KLF2 (human)
GCACGCACACAGGTGAGAAG
ACCAGTCACAGTTTGGGAGGG
VEGF (human)
GGCCTCCGAAACCATGAACTTTCTGCT
GCATGCCCTCCTGCCCGGCTCACCGC
VEGF (rat)
CTGCTGTCTTGGGTGCATTGG
CACCGCCTTGGCTTGTCACAT
β-actin
(human and rat)
CCTCTATGCCAACACAGTGC
CATCGTACTCCTGCTTGCTG
18S (human and
rat)
GTAACCCGTTGAACCCCATT
CCATCCAACGGTAGTAGCG
was used to knock down ERK5 expression in endothe-
lial cells. Endothelial cells were transfected with ERK5
siRNAs (ON-TARGETplus siRNA, 100nmol/l; Dharmacon
Inc. Lafayette, CO) for 48hrs using siRNA transfection
reagent (DharmaFECT 4; Dharmacon Inc. Lafayette, CO) as
described before in [25]. A nontargeting siRNA (siGENOME
NonTargeting Pool; Dharmacon Inc. Lafayette, CO) with the
same concentration of ERK5 siRNA was used as a negative
control (control siRNA). siRNA knock down eﬃciency was
determined by real-time RT-PCR.
2.3. RNA Isolation and cDNA Synthesis. TRIzol reagent
(Invitrogen, Burlington, ON, Canada) was used to isolate
RN Aaspreviouslydescribedin[26].RNAwasextractedwith
chloroformfollowedbycentrifugationtoseparatethesample
into aqueous and organic phases. RNA was recovered from
the aqueous phase by isopropyl alcohol precipitation and
suspended in diethylpyrocarbonate-treated water. Total RNA
(2–4μg) was used for cDNA synthesis with High Capacity
cDNA Reverse Transcription Kit (Applied Biosystem, Foster
City, CA). The resulting cDNA products were stored at
−20
◦C.
2.4. Real-Time RT-PCR. Real-time RT-PCR was performed
using the LightCycler (Roche Diagnostics Canada, Laval,
PQ, Canada) as previously described in [27]. For a ﬁnal
reaction volume of 20μl, the following reagents were added:
10μl SYBR Advantage qPCR Premix (Clontech, Mountain
V i e w ,C A ) ,1μLo fe a c hf o r w a r da n dr e v e r s e1 0μMp r i m e r s
(Table 1), 7μLH 2O, and 1 μL cDNA template. Messenger
RNA (mRNA) levels were quantiﬁed using the standard
curve method. Standard curves were constructed by using
serially diluted standard template. The data were normalized
to 18S ribosomal RNA or β-actin RNA to account for
diﬀerences in reverse transcription eﬃciencies and the
amount of template in the reaction mixtures.Journal of Ophthalmology 3
2.5. Western Blot Analysis. Total proteins from endothelial
cells were isolated by homogenizing cells in lysis buﬀer
(contains 25mmol/l Tris·HCl, pH 7.5, 150mmol/l NaCl,
5mmol/lMgCl2,1%NP -40,1mmol/lDTTand5%gly c er ol)
and protease inhibitor (complete Mini tablet, Roche) and
phosphatase inhibitor cocktail 1 and 2 (Sigma-Aldrich,
Saint Louis, MO). Protein concentrations were determined
by bicinchoninic acid (BCA) protein assay kit (Pierce,
Rockford, IL). 30μg of protein was resolved by 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and transferred to a PVDF membrane (BIO-RAD, Hercules,
CA). The membrane was then incubated with the rabbit
antiphospho-ERK5 antibody (1:1000; Cell Signaling Tech-
nology, MA). Horseradish peroxidase-conjugated antirabbit
antibody (1:10000; Upstate Biotechnology, Charlottesville,
VA) was used for detection. The signals from the western
blots were visualized with an ECL plus chemiluminescence
detection kit (Amersham Pharmacia Biotechnology, Buck-
inghamshire, UK). Blots were stripped with ReBlot Plus
Strong Antibody Stripping Solution (Millipore Corporation,
Billerica, MA) and reprobed with ERK5 antibody (1:1000;
Cell Signaling Technology, MA). Blots were then stripped
again and reprobed with β-actin antibody (1:1000, Santa
Cruz Biotechnology, CA) as a control for protein loading.
Blots were quantiﬁed by densitometry using Mocha software
(SPSS, Chicago, IL) and the data expressed as a ratio of
phosphor-Erk5 to β-actin.
2.6. In Vitro Angiogenesis Assay. The angiogenic responses to
high glucose (25mmol/l) and ERK5 siRNA transfection were
assessedusinganinvitroMatrigelanalysis.Followingappro-
priate treatment, HMVECs were seeded in 96-well culture
platesprecoatedwithECMatrix(InVitroAngiogenesisAssay
Kit, Milipore, Billerica, MA) at 1 × 104 cells/well. Cells were
maintained in serum-free medium at 37
◦Cf o r6 h r s .T h e
tube-like structures were visualized by a Leica inverted light
microscope. Images were captured with Inﬁnity Capture
software Version 3.5.1 at ×10 magniﬁcation after 6hrs
incubation. To quantify the image of tube formation, branch
pointswerecountedinseveralrandommicroscopicﬁelds(3–
5) per sample and the values averaged. At least 3 diﬀerent
cultureswerecountedperexperimentalgroup.Thedatawere
expressed as number of branch points per100× ﬁeld.
2.7. Animal Experiments. Male Sprague-Dawley rats
(Charles River) weighing between 200 and 250g were used.
Diabetes was induced by a single intravenous injection
of streptozotocin (65mg/kg, in citrate buﬀer, pH 5.6).
Age-and sex-matched rats were used as controls and given
equal volume of citrate buﬀer [28]. The animals were
monitored for glucosuria and ketonuria (Uriscan Gluketo;
Yeong Dong, Seoul, South Korea). All diabetic rats were
implanted with slow release insulin implants to prevent
ketosis (approximately 2U/day) (LinShin, Scarborough,
ON,Canada).Theyweresacriﬁcedafter4monthofdiabetes.
We have previously demonstrated that they develop diabetes
induced tissue damage in the retina and kidney at this
time [29]. The eyes were immediately enucleated, lens and
vitreous removed. The retinas of the right eye were gently
peeled oﬀ, snap-frozen in liquid nitrogen, and stored at
−70
◦C. The left retinas were ﬁxed in 4% paraformaldehyde
(PFA), as described before in [5] .A l la n i m a l sw e r ec a r e d
for according to the Association for Research in Vision and
Ophthalmology’s Guiding Principles in the Care and Use of
Animals. All experiments were approved by the University of
Western Ontario Council on Animal Care Committee.
2.8. Immunohistochemistry. Formalin ﬁxed retinal tissues
were embedded in paraﬃn, sectioned at 4μM thickness,
and placed on positively charged slides for phosphor-
ERK5 (pERK5) immunohistochemical staining. Brieﬂy, the
sections were incubated with rabbit anti-pERK5 anti-
body (Invitrogen, Carlsbad, CA, USA) at 1:200 dilutions
overnight at 4◦C, followed by incubation with labeled
polymer-HRP anti-rabbit antibody (Dako North America,
Carpinteria, CA, USA) for 30 minutes at room tempera-
ture. Visualization was conducted using diaminobenzidine
(DAB, Dako North America, Carpinteria, CA, USA) as
HRP substrate. Slides were counterstained with Hema-
toxylin. Staining with nonimmune rabbit serum instead of
primary antibodies was used as negative controls. Images
were recorded by an Olympus BX51 microscope (Olympus
Canada Inc, ON, Canada) with Northern Eclipse software
(Empix Inc, ON, Canada).
2.9. Statistical Analysis. Data were presented as the mean ±
standard error. Statistical signiﬁcance of diﬀerence between
groups was tested using Student’s t-test or if there were
more than two groups, using one way analysis of variance
(ANOVA) followed by posthoc analysis. A P value of .05 or
less was considered to be signiﬁcant. All calculations were
performed using SPSS version 15.0.
3. Results
3.1. Glucose Caused ERK5 Alteration and VEGF Upregula-
tion. We initially established whether in the ECs, glucose
causes any alteration of ERK5 signaling. No change in the
mRNA expression of ERK5 and its downstream molecules
MEF2C, KLF2, or VEGF were seen after exposure of the
cells to 25mmol/l glucose (HG) for 1 hour compared to
5mmol/l glucose (LG) (Figures 1(c)–1(f)). L-glucose was
used as an osmotic control (OC). Following 24hrs of
glucose exposure, ERK5 signaling was signiﬁcantly activated
as evidenced by increased phosphorylation (Figures 1(a)
and 1(b)) and mRNA expression of ERK5 (Figure 1(c))a n d
augmented mRNA expression of MEF2C (Figure 1(d))a n d
KLF2 (Figure 1(e)), which are downstream mediators of
ERK5signaling.Interestingly,atthistimepointtherewereno
increasesofVEGFmRNAexpression(Figure 1(f)).However,
with increased duration of high-glucose treatment (48hrs),
ERK5 phosphoryation and mRNA expression (Figures 1(a)–
1(c))a sw e l la sM E F 2 Ca n dK L F 2m R N Ae x p r e s s i o n
(Figures 1(d) and 1(e)) were decreased, while VEGF mRNA
expression was increased (Figure 1(f)). Similar results were
also observed after 72hrs of HG treatment (data not shown).4 Journal of Ophthalmology
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Figure 1:(a)RepresentativeWesternBlotshowingincreasedpERK5andtotalERK5after24hrsHGtreatmentwhichsubsequentlydecreased
after 48hrs. (b): Densitometric quantiﬁcation of pERK5 expression. (c–f): Real-time PCR showed that following incubation in HG, ERK5,
MEF2C and KLF2 mRNA expression were increased after 24hrs and then were decreased after 48hrs. On the other hand, VEGF mRNA
expression did not increase until after 48hrs of HG treatment. LG : 5mmol/l D-glucose; OC: osmotic control, 25mmol/l L-glucose;
HG: 25mmol/l D-glucose. [Data in “B” are expressed as a ratio to β-actin. mRNAs are expressed as a ratio to 18S, normalized to controls, ∗
signiﬁcantly diﬀerent from LG, n = 3 −6/group.]Journal of Ophthalmology 5
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Figure 2: ERK5 siRNA transfection reduced basal (5mmol/l, LG) and glucose induced (25mmol/l, HG) mRNA expression of ERK5 (a),
MEF2C (b), KLF2 (c) in endothelial cells after 24hrs of HG treatment. On the other hand, such transfection augmented VEGF mRNA
expression (d). [Data are expressed as a ratio to β-actin, normalized to controls, ∗: signiﬁcantly diﬀerent from control siRNA in LG, ∗∗:
signiﬁcant diﬀerence from control siRNA in HG, n = 6/group].
Since expression of total ERK5 was also changed after
glucose treatment, western blot of pERK5 was normalized
to β-actin. To further delineate the mechanistic role and
signiﬁcance of glucose-induced ERK5 activation, especially
with its regulatory eﬀects on VEGF expression, gain and loss
of function studies were performed.
3.2. ERK5 Downregulation Led to Increased VEGF Expression.
Our initial investigation indicated that VEGF mRNA expres-
sion was inversely related with ERK5 activation following
high-glucose treatment. To further explore the interaction
of ERK5 signaling and VEGF expression, loss of function
study was performed in the HMVECs using ERK5 siRNA.
ERK5 siRNA was transfected to endothelial cells to knock
downERK5gene.Real-timePCRanalysesdemonstratedthat
such transfection led to >7 0 %r e d u c t i o no fE R K 5m R N A
expression (Figure 2(a)). ERK5’s downstream substrates,
MEF2C and KLF2, were also signiﬁcantly reduced (Figures
2(b) and 2(c)). As expected, VEGF mRNA expression was
increased following ERK5 siRNA transfection measured by
real-time PCR (Figure 2(d)). To further study the eﬀect of
ERK5 knockdown on glucose induced VEGF upregulation,
HMVECs were transfected with ERK5 siRNA and then
treated with high glucose for short period (24hrs). Results
showed that ERK5 siRNA transfection abolished high-
glucose-induced increase of ERK5, MEF2C, KLF2 mRNA
(Figures 2(a)–2(c)), whereas promoted upregulation of
VEGF mRNA (Figure 2(d)).
3.3. Functional Signiﬁcance of Glucose-Induced–ERK5
Mediated VEGF Upregulation. We further expanded
the investigations to examine functional signiﬁcance of
glucose-induced ERK5 mediated VEGF expression. As
glucose-induced VEGF upregulation plays an important
role in neovascularization in proliferative DR, we examined
whether alteration of ERK5 and subsequent change in VEGF
has any eﬀects on endothelial tube formation using and an
in vitro angiogenesis assay. High-glucose treatment (48hrs)
stimulated branching and tube formation in endothelial
cells transfected with control siRNA (Figures 3(a) and 3(b)),
which was similar as our ﬁnding in endothelial cells without
transfection (data not shown). Glucose induced tube forma-
tion paralleled increased VEGF mRNA expression measured
by real-time PCR (Figure 1(e)). Endothelial cells transfected
with ERK5 siRNA rapidly formed capillary-like tube
structures (Figure 3(c)). High-glucose treatment further6 Journal of Ophthalmology
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Figure 3: ERK5 siRNA enhanced tube formation in ECs under normal and high glucose conditions. (a–d): Representative phase-contrast
photographs of in vitro angiogenesis assay showing tube formation in ECs. Such tube formations were pronounced following ERK5
siRNA transfection ((c) and (d)), compared with control siRNA transfection ((a) and (b)), both in 5mmol/l (LG) or 25mmol/l (HG)
glucose. Original magniﬁcation at 100x. (e): Quantiﬁcation of tube formation by counting branch points of tube-like structures conﬁrmed
stimulatoryeﬀect ofERK5siRNAontubeformation.[Dataareexpressed asnumberofbranchpointsper100×ﬁeld, ∗ signiﬁcantlydiﬀerent
from control siRNA in LG, †: signiﬁcant diﬀerence from control siRNA in HG, n = 3/group].
augmented the number and size of tube-like structure
formation (Figure 3(d)). Quantiﬁcation of tube formation
is shown in Figure 3(e).S u c hi n c r e a s ei nt u b ef o r m a t i o n
was associated with pronounced VEGF mRNA expression
(Figure 2(d)). These results suggest that decreased ERK5
stimulates angiogenesis by increasing VEGF expression.
3.4. ERK5 Upregulation Inhibited VEGF Expression in
EndothelialCells. WetheninvestigatedwhetherERK5upreg-
ulation can protect endothelial cells in pathological condi-
tionsmediatedbyglucose.Asglucose-inducedtissuedamage
ismediatedbyvasoactivefactorssuchasVEGF,weproceeded
to examine whether glucose induced upregulation of VEGF
mRNA can be prevented by constitutively active MEK5
(CAMEK5).
MEK5 is a speciﬁc MAPK kinase for ERK5 [13, 30, 31].
Hence, use of CAMEK5 adenovirus to upregulate ERK5
signaling is a rational approach. CAMEK5 not only activated
ERK5 phosphorylation, but also augmented ERK5 tran-
scription (Figures 4(a) and 4(b)). Western Blot conﬁrmed
increased pERK5 after CAMEK5 infection in HMVECs
(Figure 4(a)). Real-time PCR showed that ERK5 mRNA levelJournal of Ophthalmology 7
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Figure 4: In ECs, constitutionally active MEK5 (CAMEK5) caused increased ERK5 phosphorylation as indicated by (a) Western blot using
phospho ERK5 antibody. CAMEK5 also caused mRNA upregulation of ERK5 (b), KLF2 (c) and downregulation of VEGF (d). Twenty-four
hours exposure of 25mmol/l of glucose (HG) signiﬁcantly decreased VEGF mRNA expression after CAMEK5 infection (e). [mRNAs are
expressed as a ratio to 18S, normalized to control, n = 5/group, ∗: signiﬁcantly diﬀerent from untreated or GFP controls, †: signiﬁcantly
diﬀerent from other groups].
after CAMEK5 infection was signiﬁcantly higher than that
of GFP control and untreated control (Figure 4(b)). ERK5
activation caused upregulation of KLF2 mRNA expression
(Figure 4(c)) and downregulation of VEGF mRNA expres-
sion. (Figure 4(d)).
To study the eﬀect of CAMEK5 on glucose-induced
VEGF expression, HMVECs was infected with CAMEK5 and
then treated with high glucose for 24hrs. VEGF mRNA
was slightly decreased by CAMEK5-induced activation of
ERK5 in LG groups, while constitutive activation of ERK5
by CAMEK5 infection led to a signiﬁcant decrease of VEGF
after HG treatment (Figure 4(e)).
3.5. Reduced ERK5 Activation Is Associated with Increased
VEGF mRNA Expression in Retinas of Diabetic Rats. From
the perspective of DR, it is important to examine whether
the alterations demonstrated in the endothelial cells are
indeed important in a clinically relevant model of diabetic
retinal microangiopathy. Hence, we investigated retinas from8 Journal of Ophthalmology
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Figure 5: Immunohistochemical staining of pERK5 in the retina showing reduced pERK5 protein expression in the retina of diabetic rats
(b) compared to the control animals (a). Positive pERK5 staining was localized in the ganglion cell and inner nuclear layers (arrows). Inset
is an enlarged view of a microvessel showing positive pERK5 staining in the endothelial cells. Real-time PCR analysis showed reduced KLF2
(c) and augmented VEGF (d) mRNA expression in the retina of diabetic rats compared to the controls. [Original magniﬁcation at 100x.
mRNAs are expressed as a ratio to 18S, normalized to control, n = 5/group, ∗ signiﬁcantly diﬀerent from controls.]
a well-established model of diabetic retinal microangiopa-
thy. Phospho-ERK5 immunohistochemical staining was
performed in the retinal tissues of STZ-induced diabetic
rats after 4 month of followup. Diabetic animals showed
increased blood glucose levels, reduced body weight gain,
glucosuria, and occasional ketonuria (data not shown).
Positive pERK5 staining was localized in the ganglion cell
layer and in the inner nuclear layer. Microscopic exam-
ination further revealed that such positivity was in the
microvasculature as well as in other cells. The number of
positive cells and the intensity of staining were reduced
in the retina of diabetic animals compared with that of
controls (Figures 5(a) and 5(b)). We also examined the
mRNA expression of ERK5, KLF2, and VEGF in retinal
tissues of 4-month diabetic and control rats. Real-time
PCR showed that ERK5 mRNA expression in diabetic
group was too low to be detected (data not shown).
In parallel, mRNA expression of KLF2, a downstream
molecule of ERK5 signaling, in diabetic group was markedly
lower than that of control group (Figure 5(c)). In keeping
with our previous data from our lab and others, real-
time PCR analyses demonstrated a signiﬁcant increase of
VEGF mRNA expression in the retina of diabetic rats
(Figure 5(d)).Journal of Ophthalmology 9
4. Discussion
Here we have demonstrated a novel mechanism of glucose
mediated VEGF gene upregulation in diabetes. We have
shown that in the ECs glucose causes transient activation of
ERK5 followed by deactivation. Reduced activity of ERK5
was associated with upregulation of VEGF mRNA and
a n g i o g e n e s i s .W eh a v ec o n ﬁ r m e ds u c hn e g a t i v er e g u l a t i o n
of ERK5 on VEGF using ERK5 silencing and overexpression.
Furthermore, we have found similar alteration of ERK5 and
VEGF in the retina of diabetic animals.
A substantial body of evidence indicates that VEGF
is a major angiogenic factor involved in DR [32, 33].
MAPK signaling pathways play essential roles in modulating
expression of VEGF [34]. Constitutive activation of ERK1/2
elevated expression of VEGF mRNA [35]. Overexpression of
p38 and JNK activation increased halﬂife of VEGF mRNA
[36]. In addition, knockout animal study showed that JNK
regulated VEGF expression at the transcriptional level in
hypoxia induced retinal VEGF production [37]. A recent
publication revealed that Wnt signaling is activated in DR
and upregulates VEGF expression [38]. On the other hand
ERK5, as demonstrated in this paper, is the only protective
signaling that is activated by high glucose. In this study,
we examined the eﬀect of ERK5 on high-glucose-induced
VEGF expression and demonstrated a novel pathway that
potentially contributes to VEGF expression and subsequent
angiogenesis in DR.
ERK5 is diﬀerent from other MAPKs because of its
uniqueC-terminal,whichcontainstranscriptionalactivation
domain. Transcriptional activation can enhance the eﬀect of
ERK5 signaling [30]. Hence, we examined ERK5 transcrip-
tion in our study which paralleled its downstream eﬀects.
Expression of this transcription domain is suﬃcient to drive
MEF2 and regulate MEF2-dependent gene expression [39].
The importance of transcriptional activation ERK5 have
also been previously demonstrated by its eﬀects on inhi-
bition of ERK5 SUMOylation and prevention of diabetes-
mediated left ventricular dysfunction [40]. However, ERK5
also activates signaling using traditional phosphorylation
[41]. Studies have shown that the activated kinase activity
of ERK5 undergoes autophosphorylation on its most C-
terminal region, which is required for the C-terminal-
half to enhance the ERK5 activity [30]. In this study we
have demonstrated both attenuated ERK5 transcription and
phosphorylation in high-glucose treated endothelial cells.
Our data indicate that both mechanisms may be operating
in glucose-induced VEGF upregulation.
It has been previously reported that MEF2-KLF2
counteracted VEGF-mediated inﬂammatory responses in
endothelial cells [22]. In addition, KLF2, a downstream
molecule of ERK5, is a transcriptional regulator of angio-
genesis, and overexpression of KLF2 counteracts VEGF-
mediated angiogenesis due to a potent inhibition of VEGFR2
expression and promoter activity [21]. Our study found that
reduced ERK5, MEF2C, and KLF2 expression were along
with increased VEGF level after 48hrs glucose exposure
(Figure 1). On the other hand, after 24hrs, although ERK5
was activated, we failed to observe VEGF upregulation.
Exact reason for such ﬁndings is not clear. Possible expla-
nation may include other regulatory factors and cell speciﬁc
factors, which need further characterization. Nevertheless,
ERK5 siRNA transfection signiﬁcantly reduced MEF2C and
KLF2 mRNA expression (Figure 4), suggesting that ERK5
negatively regulates VEGF through MEF2C and KLF2 upon
high glucose treatment. Under hypoxic conditions, ERK5
inhibits VEGF via hypoxia inducible factor 1α (HIF1α)i n
endothelial cells [18]. In addition, it has been shown that
KLF2 inhibits HIF1a and hypoxia-mediated angiogenesis
[42]. High glucose induced a state of pseudo-hypoxia in
diabetic complications [43, 44]. It is therefore possible
that depletion of ERK5/KLF2 signaling may promote high
glucose-induced angiogenesis via HIF1a. However, such
notion has to be further established by speciﬁc experiments.
In keeping with our ﬁnding it has been demonstrated
thatERK5activationisinducedtransientlybyhighglucosein
endothelial cells, which ultimately decreased after long-term
treatment [45]. As following long-term glucose exposure in
ECs and in the retina of chronically diabetic animals, similar
pattern of ERK5 and VEGF were seen, it is possible that in
long-term diabetes inhibitory eﬀects of ERK5 is lost, leading
to VEGF upregulation. In this study we have seen VEGF
upregulation after 48hrs. This is in keeping with studies in
endothelial cells from other sources [9, 46]. Some studies
have demonstrated VEGF upregulation following a short
period of glucose exposure. Various sources of cells and
culture conditions may in part be responsible for such dis-
crepancy. In addition simultaneously other mechanisms may
also be responsible for glucose induced VEGF upregulation.
Both PKC and ERK1/2 activation have been demonstrated to
regulate VEGF in glomerular podocytes [47]. In this study
we observed that after 24hrs glucose treatment, although
there was signiﬁcant activation of ERK5, there were no
signiﬁcant downregulation of VEGF in this system. This
suggests that other mechanisms mentioned above may also
modulate glucose-induced VEGF, further investigation is
required to delineate the relationship of ERK5 and other
signaling pathways.
Itiswellestablishedthatoxidantandshearstresscanreg-
ulate ERK5 alteration. Exact mechanism of glucose induced
ERK5 alteration is still not known, however it is possible
that glucose-induced oxidative stress is a key player in ERK5
change. Growth factors such as epidermal growth factor
(EGF) and nerve growth factor (NGF) activate ERK5 [48,
49]. Hence several additional mechanisms may potentially
regulate glucose induced ERK5 alteration. We, however,
understand some of the limitations of this study as the
in vitro experiments were performed in the microvascular
cells of nonretinal origin. We tried to address some of
these problems with simultaneous experiments at levels of
complexities, that is, retinal tissues. However, additional
future studies are needed in various cell types to further
characterize these changes.
In summary, this is the ﬁrst study to show that ERK5
may potentially regulate VEGF upon high-glucose treatment
in the ECs and in the retina of diabetic rats. Although this
study was done in the context of diabetic retinopathy, it is
possible that such process is of importance in other diabetic10 Journal of Ophthalmology
complications involving VEGF signaling. ERK5 may also
provide an attractive target for drug development in DR and
other diabetic vascular complications.
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